More importantly, many PDE4 inhibitors under development are effective in animal models of inflammatory diseases, including asthma, COPD, psoriasis, IBD, and rheumatoid arthritis (Peng et al., 2020). Here, PDE4A is linked to inflammatory bowel disease.